NCT01722656

Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment

Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Southern California Desert Retina Consultants, MC · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the use of intravitreal aflibercept (anti-VEGF therapy) in patients with a type of macular degeneration known as vascularized pigment epithelial detachment. Previous studies have shown a generally poor outcome in treating this difficult to treat form of wet macular degeneration. More recently, multiple pilot studies have shown positive benefits to using anti-VEGF therapy. This study will evaluate the safety and efficacy of treating vascularize pigment epithelial detachment associated with wet macular degeneration with intravitreal aflibercept injection.

Conditions

• Submacular Vascularized Pigment Epithelial Detachments

Interventions

Type	Name	Description
DRUG	Aflibercept

Timeline

• Start date: 2012-11-01
• Primary completion: 2015-09-01
• Completion: 2015-09-01
• First posted: 2012-11-07
• Last updated: 2016-01-22

Locations

3 sites across 1 country: United States